COLUMBIA, MD -- DDI – 2007 - 10th International Conference on Drug-Drug Interactions: Scientific and Regulatory Updates and DDI Technologies in Depth:
Enzyme Inhibition, Enzyme Induction and Drug-Transporter Interactions
Pre-Conference Workshop: In Vitro Evaluations of ADMET Drug Properties in Drug Development June 24-26, 2007 - Bellevue, WA, USA
Sunday, June 24, 2007 Preconference Workshop
In Vitro Evaluations of ADMET Drug Properties in Drug Development (Chair: Albert P. Li)
• Role of In Vitro Experimental Systems in Drug Development (Albert P. Li, APSciences Inc. and IVAL/BRIVAL, Columbia MD and Vancouver, BC)
• Metabolic Stability and Drug-Drug Interactions (Chuang Lu, Millennium Pharmaceuticals Inc.; Cambridge, MA)
• Enzyme Induction (Nicky Hewitt, CellzDirect; Pittsboro, NC)
• Transporters (Cindy Xia, Millennium Pharmaceuticals Inc.; Cambridge, MA)
• Toxicity Screening (Albert P. Li, APSciences Inc. and IVAL/BRIVAL, Columbia MD and Vancouver, BC)
• In Vitro ADME Screening Assays for Early Drug Discovery (Lilly Xu, Amgen; Thousand Oaks, CA)
• LC/MS and LC/MS/MS Applications in ADME Studies (David Kwok, BRI Biopharmaceutical Research Inc.; Vancouver, BC)
• Bioluminescent Approaches For In Vitro ADME/Tox (Jim Cali, Promega; Madison, WI)
Monday, June 25, 2007 - Main Conference: DDI-2007
Welcoming remarks: Rene Levy, University of Washington, Seattle, WA
Session 1: Scientific and Regulatory Updates (Chair: Rene Levy)
• What is new in 2006-2007? (Isabelle Ragueneau-Majlessi, University of Washington; Seattle, WA)
• Recently Approved Drugs: Drug Interaction Information in Labeling (Carol Collins, University of University, Seattle, WA)
• FDA Guidance Document (Kenneth Thummel, University of Washington; Seattle, WA)
Session II: In Vitro: In Vivo Extrapolation of Enzyme Inhibition Studies (Chair: Chuang Lu)
• In Vitro Drug-Drug Interaction Evaluation Using Intact Hepatocytes and 100% Human Plasma (Chuang Lu, Millennium Pharmaceuticals, Inc.; Cambridge, MA)
• Prediction of Cytochrome P450-Based Drug-Drug Interactions from In Vitro Inhibition and Inactivation Data (Robert L. Walsky, Pfizer Inc., Groton, CT)
• Mechanism-Based Enzyme Inhibition: A Critical Look at In Vitro Study Design and Implications for In Vitro-In Vivo Extrapolation (G.T. Tucker, University of Sheffield & Simcyp Ltd, Sheffield UK)
• Prediction of Time-dependent Inactivation of CYP3A in Hepatocytes: Evaluation of the Use of Microsomal Parameters to Predict Pharmacokinetic Drug Interactions. (Ping Zhao, Kent L Kunze1, Caroline A Lee2, Sonus Pharmaceuticals Inc, Bothell, WA; 1University of Washington, Seattle, WA; 2Pfizer Global Research and Development, San Diego, CA)
• Prediction of Human Drug-Drug Interactions from Mechanism-Based CYP3A4 Inhibition in Human Hepatocytes (Lilly Xu, Amgen Inc.; Thousand Oaks, CA)
• Role of Inhibitory Metabolites in Drug-Drug Interactions (Nina Isoherranen, University of Washington; Seattle, WA
Session III: Enzyme inhibition by Natural Products (Chair: David Greenblatt)
• In Vitro-In Vivo Disconnection: Studies of Nutrients and Natural Substances (David J. Greenblatt, Tufts University School of Medicine; Boston MA)
• Esterase Inhibition Attribute of Grapefruit Juice Leading to a New Drug Interaction (Suresh Balani, Millennium Pharmaceuticals, Cambridge, MA)
Tuesday, June 26, 2007
Session IV: Enzyme Induction (Chair: Ed LeCluyse)
• Assessing Enzyme Induction In Vitro: A Scientific and Regulatory Perspective (Edward L. LeCluyse, CellzDirect, Inc.; Pittsboro, NC)
• Protocols for Enzyme Induction Studies (Nicky Hewitt, CellzDirect, Inc.; Pittsboro, NC)
• Human Hepatocyte Cryopreservation and Enzyme Induction (Albert P. Li, APSciences Inc. and IVAL/BRIVAL, Columbia MD and Vancouver, BC)
Session V: Transporters (Chairs: Cindy Xia & Mary Paine)
• Evaluation of Drug-Transporter Interactions Using In Vitro and In Vivo Models (Cindy Xia, Millennium Pharmaceuticals, Inc.; Cambridge, MA)
• Role of Transporters in Different Therapeutic Areas: From Systemic Disposition to Cellular Localization (Lisa von Moltke, Millennium Pharmaceuticals, Inc; Cambridge, MA)
• Valsartan Interaction with Uptake and Efflux Transporters (Imad Hanna, Natalya Alexander, Novartis Pharmaceuticals Corporation, East Hanover, NJ)
• Transporter Mediated Drug-Drug Interactions: Prediction of Clinical Outcome from In Vitro Data (Mitchell E. Taub, Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT)
• Role of Hepatic Transporters in the Disposition of Rosuvastatin (Liyue Huang, Amgen Inc.; Cambridge, MA)
• Intestinal Drug Metabolism and Transport (Mary Paine, University of North Carolina, Chapel Hill, NC)
• Evaluation of Multidrug Resistance-linked P-glycoproteins from Mammalian Species Used in Preclinical Studies (Suresh V. Ambudkar, National Cancer Institute, NIH, Bethesda, MD)
Please visit us online at www.isciencex.com
###
